Merck KGaA
OTC:MKGAF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (41.1), the stock would be worth $415.28 (213% upside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.1 | $132.81 |
0%
|
| 3-Year Average | 41.1 | $415.28 |
+213%
|
| 5-Year Average | 50.3 | $508.47 |
+283%
|
| Industry Average | 22 | $222.19 |
+67%
|
| Country Average | 22 | $222.19 |
+67%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
|
Merck KGaA
OTC:MKGAF
|
47.8B USD | 13.1 | 18.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 61.3 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 37.8 | 4 516.9 |
Market Distribution
| Min | 0.3 |
| 30th Percentile | 12.8 |
| Median | 22 |
| 70th Percentile | 33.7 |
| Max | 8 508.8 |
Other Multiples
Merck KGaA
Glance View
In the heart of Darmstadt, Germany, Merck KGaA stands as a testament to innovation and resilience, tracing its roots back to 1668. A bastion of scientific advancement and a pioneer in the world of chemistry and pharmaceuticals, Merck has evolved through centuries of discovery and transformation. Originally a humble pharmacy, Merck has grown into a global powerhouse with a unique structure, being one of the oldest pharmaceutical and chemical companies in the world still owned by the founding family. Though its path has been influenced by numerous historical events, Merck has adeptly navigated the shifting sands of time, transforming itself into a multifaceted conglomerate that thrives on its dual strategy—life sciences and performance materials. In the modern age, Merck KGaA operates through three well-defined sectors: Healthcare, Life Science, and Electronics. Its Healthcare division plays a formidable role, developing innovative drugs, with a focus on oncology, neurology, and immunology, providing cutting-edge treatments that improve patient lives globally. Meanwhile, the Life Science arm caters to researchers and scientists, offering an extensive portfolio of lab materials, high-tech tools, and equipment essential for groundbreaking research across various industries. The Electronics division, dedicated to performance materials, supplies high-quality substances crucial for the electronics and automotive industries, including liquid crystals and highly sophisticated semiconductor solutions. Through these divisions, Merck KGaA not only generates substantial revenue but also drives progress by supplying critical products that are indispensable to the modern technological landscape.